Which Wegovy dose leads to the most weight loss?

You've been on 0.5 mg for a month and the scales haven't shifted

That's almost expected. Wegovy's titration schedule exists to protect your digestive system, not to produce rapid early results. The 0.25 mg and 0.5 mg levels are stepping stones. Semaglutide suppresses appetite through GLP-1 receptor activation, which also slows the rate at which your stomach empties, and your body needs time to adjust to that before the dose rises enough to produce consistent weight change.

The question of whether you can lose weight on the starting dose of Wegovy is one many people ask in those early weeks. Some do see modest movement; others notice very little until the dose climbs past 1.0 mg. Neither pattern means the medicine isn't working. What matters is that nausea and other GI symptoms remain manageable so you can keep titrating upward, which is where the meaningful results accumulate.

A useful thing to do right now: note today's weight and set a calendar reminder four weeks out. A single morning weigh-in on the same day each month, at the same time, gives you a clean data point your prescriber can actually use when reviewing your next dose step.

The full Wegovy dose schedule explains each step in detail, including the minimum time spent at each level before moving up.

What the trial data actually show at each maintenance level

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults without diabetes for 68 weeks. At the 2.4 mg maintenance dose, participants lost around 15% of their body weight on average, roughly five times what the placebo group achieved alongside the same lifestyle support. That figure is an average; some people lost considerably more, others less. The result established 2.4 mg as the standard maintenance dose under the original UK licence.

The picture shifted in early 2026. On 12 January 2026 the MHRA authorised a higher 7.2 mg semaglutide dose, and on 14 April 2026 it approved a dedicated single-dose 7.2 mg pen, making the UK the first country in Europe to offer this option. Trial data at 7.2 mg recorded around 20.7% average weight loss over 72 weeks, bringing semaglutide's top-dose results closer to those seen with tirzepatide at its highest level.

The 1.7 mg intermediate dose falls between the two maintenance thresholds — some people remain there long-term if 2.4 mg causes persistent side effects they can't tolerate. Weight loss at 1.7 mg is real but typically more modest than at full maintenance. Many people also wonder whether lower doses of Wegovy can still produce meaningful weight loss, and the answer depends largely on individual response and how long you stay at that level. If you're considering where Wegovy sits in the range of licensed weight-loss treatments, it's worth understanding that maximum benefit depends on reaching and sustaining the highest dose your body handles well, not just starting the medicine.

Why the 7.2 mg pen is not simply the next step for everyone

The MHRA's April 2026 approval of the single-dose 7.2 mg pen carries a specific restriction: it is licensed for adults with a BMI of 30 or above, only for the weight management indication. It is not approved for the cardiovascular risk-reduction use case, and it is not for people with a BMI below 30. The titration pathway to 7.2 mg still begins at 0.25 mg and escalates through the established steps at roughly four-weekly intervals, no one starts at the higher dose.

Whether a patient progresses to 7.2 mg depends on how they've tolerated lower doses and whether there is a clinical reason to push higher. That decision sits entirely with the prescriber. Our clinical team reviews this kind of progression individually, looking at weight-loss trajectory, reported side effects and overall health context.

One point worth understanding about the NHS route: NICE's appraisal of Wegovy (TA875) recommends it only within specialist weight management services, for a maximum of two years, and with strict BMI and comorbidity criteria. NHS waiting lists for those services can be long. For people who don't meet the NHS thresholds yet, or who prefer not to wait, a private prescription through a regulated pharmacy is the legal alternative, and the process of getting Wegovy privately starts with a clinical consultation, not a basket.

The dose that produces the most weight loss is the one you can stay on

This sounds obvious but it's the part that gets lost in the conversation about which number is highest. Reaching 7.2 mg matters far less than sustaining 2.4 mg consistently if 7.2 mg causes you to stop treatment early. Persistent nausea, vomiting or other GI side effects at a given dose are your body's signal that the pace may need to slow. A prescriber may hold you at a level longer, or step you back temporarily, rather than push through.

The right Wegovy dosage for weight loss is not a fixed answer, it's a clinical judgement that evolves as you go. People who reach their personal highest-tolerated dose and stay there, alongside reduced-calorie eating and regular movement, see the best outcomes the trials recorded. Those who stop midway through titration, or start and stop repeatedly, do not.

If you'd like a prescriber to review your situation and work out which dose makes sense for you, start your free consultation with nume today. Every review is carried out by a GPhC-registered Independent Prescriber, on the same day.